Vericel Corporation $VCEL Shares Sold by Kopp Family Office LLC

Kopp Family Office LLC trimmed its position in shares of Vericel Corporation (NASDAQ:VCEL) by 68.7% during the second quarter, Holdings Channel reports. The institutional investor owned 51,053 shares of the biotechnology company’s stock after selling 112,302 shares during the quarter. Vericel comprises about 1.4% of Kopp Family Office LLC’s portfolio, making the stock its 13th largest holding. Kopp Family Office LLC’s holdings in Vericel were worth $2,271,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the company. State Street Corp lifted its stake in Vericel by 12.7% in the fourth quarter. State Street Corp now owns 3,163,922 shares of the biotechnology company’s stock worth $113,933,000 after acquiring an additional 356,680 shares during the last quarter. GW&K Investment Management LLC increased its position in shares of Vericel by 22.5% in the 4th quarter. GW&K Investment Management LLC now owns 1,580,967 shares of the biotechnology company’s stock valued at $56,931,000 after purchasing an additional 290,795 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Vericel by 133.6% in the 4th quarter. Goldman Sachs Group Inc. now owns 497,167 shares of the biotechnology company’s stock valued at $17,903,000 after purchasing an additional 284,305 shares during the last quarter. Woodline Partners LP acquired a new stake in shares of Vericel in the 3rd quarter valued at $8,409,000. Finally, Fifth Third Bancorp raised its holdings in shares of Vericel by 20,888.4% in the 1st quarter. Fifth Third Bancorp now owns 256,688 shares of the biotechnology company’s stock valued at $8,258,000 after purchasing an additional 255,465 shares in the last quarter.

Analyst Ratings Changes

Several equities research analysts have recently issued reports on the stock. TD Cowen lifted their price objective on shares of Vericel from $55.00 to $58.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Wall Street Zen upgraded Vericel from a “hold” rating to a “buy” rating in a research note on Saturday, July 18th. Truist Financial reaffirmed a “buy” rating and set a $58.00 price target (up from $54.00) on shares of Vericel in a report on Friday, July 31st. HC Wainwright reaffirmed a “buy” rating and set a $70.00 price objective on shares of Vericel in a research report on Tuesday, July 28th. Finally, Weiss Ratings upgraded Vericel from a “sell (d+)” rating to a “hold (c)” rating in a report on Friday, July 31st. Four equities research analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $58.40.

Insider Transactions at Vericel

In related news, insider Sean C. Flynn sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $45.64, for a total transaction of $684,600.00. Following the transaction, the insider owned 1,647 shares in the company, valued at $75,169.08. This trade represents a 90.11% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Joseph Anthony Mara, Jr. sold 5,000 shares of Vericel stock in a transaction that occurred on Friday, June 26th. The stock was sold at an average price of $44.75, for a total value of $223,750.00. Following the transaction, the chief financial officer directly owned 16,009 shares in the company, valued at approximately $716,402.75. This trade represents a 23.80% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 52,232 shares of company stock valued at $2,304,217 in the last 90 days. Company insiders own 7.60% of the company’s stock.

Vericel Price Performance

NASDAQ VCEL opened at $43.95 on Tuesday. Vericel Corporation has a 1 year low of $28.95 and a 1 year high of $49.32. The company has a market capitalization of $2.25 billion, a PE ratio of 93.51 and a beta of 1.06. The company has a fifty day moving average of $43.30 and a two-hundred day moving average of $37.73.

Vericel (NASDAQ:VCEL) last posted its earnings results on Thursday, July 30th. The biotechnology company reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. Vericel had a return on equity of 6.91% and a net margin of 7.91%.The business had revenue of $77.46 million for the quarter, compared to analysts’ expectations of $72.70 million. During the same quarter in the previous year, the firm earned ($0.01) earnings per share. The business’s revenue was up 22.5% compared to the same quarter last year. On average, research analysts expect that Vericel Corporation will post 0.54 earnings per share for the current year.

Vericel Company Profile

Vericel Corporation is a biotechnology company specializing in the development, manufacturing and commercialization of cell-based therapies for patients with severe diseases and conditions. The company’s expertise lies in regenerative medicine, where it harnesses the power of autologous cell processing to create products designed to restore function and promote healing in damaged tissues.

Vericel currently markets two FDA-approved therapies. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is indicated for the repair of symptomatic cartilage defects of the knee in adult patients.